156 related articles for article (PubMed ID: 37942576)
1. TI17, a novel compound, exerts anti-MM activity by impairing Trip13 function of DSBs repair and enhancing DNA damage.
Chang S; Xiao W; Xie Y; Xu Z; Li B; Wang G; Hu K; Zhang Y; Zhou J; Song D; Zhu H; Wu X; Lu Y; Shi J; Zhu W
Cancer Med; 2023 Dec; 12(23):21321-21334. PubMed ID: 37942576
[TBL] [Abstract][Full Text] [Related]
2. A Small-Molecule Inhibitor Targeting TRIP13 Suppresses Multiple Myeloma Progression.
Wang Y; Huang J; Li B; Xue H; Tricot G; Hu L; Xu Z; Sun X; Chang S; Gao L; Tao Y; Xu H; Xie Y; Xiao W; Yu D; Kong Y; Chen G; Sun X; Lian F; Zhang N; Wu X; Mao Z; Zhan F; Zhu W; Shi J
Cancer Res; 2020 Feb; 80(3):536-548. PubMed ID: 31732653
[TBL] [Abstract][Full Text] [Related]
3. TRIP13 impairs mitotic checkpoint surveillance and is associated with poor prognosis in multiple myeloma.
Tao Y; Yang G; Yang H; Song D; Hu L; Xie B; Wang H; Gao L; Gao M; Xu H; Xu Z; Wu X; Zhang Y; Zhu W; Zhan F; Shi J
Oncotarget; 2017 Apr; 8(16):26718-26731. PubMed ID: 28157697
[TBL] [Abstract][Full Text] [Related]
4. The novel norcantharidin derivative DCZ5417 suppresses multiple myeloma progression by targeting the TRIP13-MAPK-YWHAE signaling pathway.
Wang Y; Dong S; Hu K; Xu L; Feng Q; Li B; Wang G; Chen G; Zhang B; Jia X; Xu Z; Gao X; Zhang H; Xie Y; Lu M; Chang S; Song D; Wu X; Jia Q; Zhu H; Zhou J; Zhu W; Shi J
J Transl Med; 2023 Nov; 21(1):858. PubMed ID: 38012658
[TBL] [Abstract][Full Text] [Related]
5. TRIP13 promotes error-prone nonhomologous end joining and induces chemoresistance in head and neck cancer.
Banerjee R; Russo N; Liu M; Basrur V; Bellile E; Palanisamy N; Scanlon CS; van Tubergen E; Inglehart RC; Metwally T; Mani RS; Yocum A; Nyati MK; Castilho RM; Varambally S; Chinnaiyan AM; D'Silva NJ
Nat Commun; 2014 Jul; 5():4527. PubMed ID: 25078033
[TBL] [Abstract][Full Text] [Related]
6. Inducing Synergistic DNA Damage by TRIP13 and PARP1 Inhibitors Provides a Potential Treatment for Hepatocellular Carcinoma.
Xu H; Ma Z; Mo X; Chen X; Xu F; Wu F; Chen H; Zhou G; Xia H; Zhang C
J Cancer; 2022; 13(7):2226-2237. PubMed ID: 35517402
[TBL] [Abstract][Full Text] [Related]
7. An inverse switch in DNA base excision and strand break repair contributes to melphalan resistance in multiple myeloma cells.
Sousa MM; Zub KA; Aas PA; Hanssen-Bauer A; Demirovic A; Sarno A; Tian E; Liabakk NB; Slupphaug G
PLoS One; 2013; 8(2):e55493. PubMed ID: 23405159
[TBL] [Abstract][Full Text] [Related]
8. The ATM signaling cascade promotes recombination-dependent pachytene arrest in mouse spermatocytes.
Pacheco S; Marcet-Ortega M; Lange J; Jasin M; Keeney S; Roig I
PLoS Genet; 2015 Mar; 11(3):e1005017. PubMed ID: 25768017
[TBL] [Abstract][Full Text] [Related]
9. TRIP13 Participates in Immediate-Early Sensing of DNA Strand Breaks and ATM Signaling Amplification through MRE11.
Jeong H; Wie M; Baek IJ; Sohn G; Um SH; Lee SG; Seo Y; Ra J; Lee EA; Kim S; Kim BG; Deshpande RA; Paull TT; Han JS; Kwon T; Myung K
Cells; 2022 Dec; 11(24):. PubMed ID: 36552858
[TBL] [Abstract][Full Text] [Related]
10. Elevated TRIP13 drives cell proliferation and drug resistance in bladder cancer.
Lu S; Guo M; Fan Z; Chen Y; Shi X; Gu C; Yang Y
Am J Transl Res; 2019; 11(7):4397-4410. PubMed ID: 31396344
[TBL] [Abstract][Full Text] [Related]
11. Upregulation of thyroid hormone receptor interactor 13 is associated with human hepatocellular carcinoma.
Ju L; Li X; Shao J; Lu R; Wang Y; Bian Z
Oncol Rep; 2018 Dec; 40(6):3794-3802. PubMed ID: 30542731
[TBL] [Abstract][Full Text] [Related]
12. Molecular mechanisms of assembly and TRIP13-mediated remodeling of the human Shieldin complex.
Xie W; Wang S; Wang J; de la Cruz MJ; Xu G; Scaltriti M; Patel DJ
Proc Natl Acad Sci U S A; 2021 Feb; 118(8):. PubMed ID: 33597306
[TBL] [Abstract][Full Text] [Related]
13. PJ34, a poly(ADP-ribose) polymerase (PARP) inhibitor, reverses melphalan-resistance and inhibits repair of DNA double-strand breaks by targeting the FA/BRCA pathway in multidrug resistant multiple myeloma cell line RPMI8226/R.
Xiong T; Wei H; Chen X; Xiao H
Int J Oncol; 2015 Jan; 46(1):223-32. PubMed ID: 25351371
[TBL] [Abstract][Full Text] [Related]
14. Increased expression of TRIP13 drives the tumorigenesis of bladder cancer in association with the EGFR signaling pathway.
Gao Y; Liu S; Guo Q; Zhang S; Zhao Y; Wang H; Li T; Gong Y; Wang Y; Zhang T; Dong Z; Bacich D; Chowdhury WH; Rodriguez R; Wang Z
Int J Biol Sci; 2019; 15(7):1488-1499. PubMed ID: 31337978
[TBL] [Abstract][Full Text] [Related]
15. DNA damage is overcome by TRIP13 overexpression during cisplatin nephrotoxicity.
Hama T; Nagesh PK; Chowdhury P; Moore BM; Yallapu MM; Regner KR; Park F
JCI Insight; 2021 Nov; 6(22):. PubMed ID: 34806647
[TBL] [Abstract][Full Text] [Related]
16. A novel M phase blocker, DCZ3301 enhances the sensitivity of bortezomib in resistant multiple myeloma through DNA damage and mitotic catastrophe.
Hu L; Li B; Chen G; Song D; Xu Z; Gao L; Xi M; Zhou J; Li L; Zhang H; Feng Q; Wang Y; Lu K; Lu Y; Bu W; Wang H; Wu X; Zhu W; Shi J
J Exp Clin Cancer Res; 2020 Jun; 39(1):105. PubMed ID: 32517809
[TBL] [Abstract][Full Text] [Related]
17. Design and synthesis of cantharidin derivative DCZ5418 as a TRIP13 inhibitor with anti-multiple myeloma activity in vitro and in vivo.
Dong S; Hu K; Shi Y; Wang G; Yu D; Zhao Y; Zhang H; Wang Y; Sun H; Xu Z; Jia Q; Li Y; Li Y; Li B; Shi J; Zhu W
Bioorg Med Chem Lett; 2024 Jan; 98():129590. PubMed ID: 38092072
[TBL] [Abstract][Full Text] [Related]
18. Preclinical validation and phase I trial of 4-hydroxysalicylanilide, targeting ribonucleotide reductase mediated dNTP synthesis in multiple myeloma.
Xie Y; Wang Y; Xu Z; Lu Y; Song D; Gao L; Yu D; Li B; Chen G; Zhang H; Feng Q; Zhang Y; Hu K; Huang C; Peng Y; Wu X; Mao Z; Shao J; Zhu W; Shi J
J Biomed Sci; 2022 May; 29(1):32. PubMed ID: 35546402
[TBL] [Abstract][Full Text] [Related]
19. Thyroid receptor-interacting protein 13 and EGFR form a feedforward loop promoting glioblastoma growth.
Hu L; Shen D; Liang D; Shi J; Song C; Jiang K; Menglin Ren ; Du S; Cheng W; Ma J; Li S; Bi X; Barr MP; Fang Z; Xu Q; Li W; Piao H; Meng S
Cancer Lett; 2020 Nov; 493():156-166. PubMed ID: 32860853
[TBL] [Abstract][Full Text] [Related]
20. Elevated TRIP13 drives the AKT/mTOR pathway to induce the progression of hepatocellular carcinoma via interacting with ACTN4.
Zhu MX; Wei CY; Zhang PF; Gao DM; Chen J; Zhao Y; Dong SS; Liu BB
J Exp Clin Cancer Res; 2019 Sep; 38(1):409. PubMed ID: 31533816
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
